Cutler Group’s Cidara Therapeutics CDTX Stock Holding History

Cutler Group’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-45	Closed	-$3K	–	4246
2018 Q1	$3K	Buy	+45	New	+$6.15K	﹤0.01%	3530

Other funds holding CDTX

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Millennium Management

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cutler Group's CDTX Position: Q2 2018 in Review

Cutler Group sold out of Cidara Therapeutics (CDTX) in Q2 2018, closing a stake of 45 shares — an estimated $3K sold.

Cutler Group first reported a position in CDTX in Q1 2018 and held it in 1 quarter. The position peaked at $3K in Q1 2018. 56 funds tracked by Wall St. Rank hold CDTX as of Q2 2018.

Cutler Group reported no remaining Cidara Therapeutics position as of Q2 2018 after selling out during the quarter.
Cutler Group sold 45 Cidara Therapeutics shares in Q2 2018, an estimated $3K.
Cutler Group first reported a position in Cidara Therapeutics in Q1 2018 and held it in 1 quarter.
Cutler Group's Cidara Therapeutics position peaked at $3K in Q1 2018.
56 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q2 2018.

Based on Cutler Group's 13F filing for Q2 2018, filed 10 Aug 2018.